ONCOLOGIEOpen Access

Oncologie

ISSN:1292-3818(print)
ISSN:1765-2839(online)
Publication Frequency:Bi-monthly

  • Online
    Articles

    1986

  • on board
    editors

    55

Special Issues



About the Journal

Oncologie is aimed to the publication of high quality original research articles, review papers, case report, etc. with an active interest in vivo or vitro study of cancer biology. Study relating to the pathology, diagnosis, and advanced treatment of all types of cancers, as well as research from any of the disciplines related to this field of interest. The journal has English and French bilingual publication.
The French Society of Oncology Surgery (SFCO), Association francophone des soins oncologiques de support (AFSOS) and the French Federation of Medical Oncologists (FFOM) are affiliated with the journal Oncologie.

Indexing and Abstracting

Science Citation Index Expanded (SciSearch): 2023 Impact Factor 1.4; Journal Citation Report/Science Edition (JCR); Scopus; Scopus Citescore (Impact per Publication 2023): 1.3; EMBASE; Google Scholar; OCLC; PASCAL; SCImago; Summon by ProQuest

Notice: Starting from Volume 25, 2023, Oncologie will be published by De Gruyter (https://www.degruyter.com/journal/key/oncologie/html). Please make new submissions of Oncologie to the new system from December 1st, 2022. (https://mc.manuscriptcentral.com/oncologie) To view your previous submissions, please access TSP system (https://tspsubmission.com/index.php/oncologie/submissions)

  • Open Access

    ARTICLE

    Impact des Thérapies Complémentaires sur la Survie de Patients Atteints d’un Cancer Traités par Chimiothérapie Orale dans un Établissement Hospitalier Français Spécialisé en Oncologie : Étude Exploratoire

    Oncologie, Vol.24, No.4, pp. 605-612, 2022, DOI:10.32604/oncologie.2022.024558 - 31 December 2022
    Abstract Une étude rétrospective observationnelle réalisée aux États-Unis montre une réduction de la survie de patients traités pour un cancer du sein, de la prostate, du poumon et colorectal en cas de déclaration d’usage de thérapies complémentaires (TC). Nous avons voulu vérifier ce résultat auprès d’une population française de 636 patients diagnostiqués des mêmes types de cancers et traités consécutivement par chimiothérapie orale dans un établissement hospitalier durant trois ans. Un entretien par un pharmacien en amont de l’administration d’une chimiothérapie orale a permis d’identifier les TC utilisées par les patients. Nous avons comparé la survie More >

  • Open Access

    REVIEW

    Advances in Targeted Therapy Against Driver Mutations and Epigenetic Alterations in Non-Small Cell Lung Cancer

    Oncologie, Vol.24, No.4, pp. 613-648, 2022, DOI:10.32604/oncologie.2022.027545 - 31 December 2022
    Abstract The incidence and mortality of lung cancer rank top three of all cancers worldwide. Accounting for 85% of the total number of lung cancer, non-small cell lung cancer (NSCLC) is an important factor endangering human health. Recently, targeted therapies against driver mutations and epigenetic alterations have made encouraging advances that benefit NSCLC patients. Druggable driver mutations, which mainly occur in EGFR, KRAS, MET, HER2, ALK, ROS1, RET and BRAF, have been identified in more than a quarter of NSCLC patients. A series of highly selective mutant targeting inhibitors, such as EGFR tyrosine kinase inhibitors and KRAS inhibitors, have been… More >

  • Open Access

    REVIEW

    Epidemiology of Breast Cancer

    Oncologie, Vol.24, No.4, pp. 649-663, 2022, DOI:10.32604/oncologie.2022.027640 - 31 December 2022
    Abstract All over the world, the most common malignancy in women is breast cancer. Breast cancer is also a significant factor of death in women. In 2020, approximately 2.3 million cases of breast cancer were newly diagnosed in women globally, and approximately 685,000 people died. Breast cancer incidence varies by region around the world, but it is all increasing. According to the current morbidity and mortality trend of breast cancer, it is estimated that by 2030, the number of incidence and deaths of breast cancer will reach 2.64 million and 1.7 million, respectively. The age-standardized incidence… More >

  • Open Access

    REVIEW

    The Emerging Role of Lymphocyte Activation Gene 3 in the Cancer Immunotherapy

    Oncologie, Vol.24, No.4, pp. 665-678, 2022, DOI:10.32604/oncologie.2022.023641 - 31 December 2022
    (This article belongs to the Special Issue: Cancer Immunotherapy)
    Abstract The emergence of tumor immunotherapy, especially immune checkpoint inhibitors (ICIs), has brought new life to cancer treatment, and ICIs can effectively treat various tumors. Among the immune anti-cancer therapies, PD-1 is undoubtedly the hot target after CTLA-4, but due to the ineffectiveness of PD-1 in treating certain tumors, researchers have shifted their focus to other combination targets, such as LAG-3, TIM3, IDO-1, etc. One of these promising targets is LAG-3, a target with multiple clinical trials, which has increasingly shown to be an inhibitory co-receptor that plays a vital role in autoimmunity, cancer immunity, and More >

  • Open Access

    REVIEW

    Ferroptosis’s Role in Genitourinary System Cancer

    Oncologie, Vol.24, No.4, pp. 679-691, 2022, DOI:10.32604/oncologie.2022.025705 - 31 December 2022
    (This article belongs to the Special Issue: Ferroptosis in the Occurrence and Treatment of Cancer)
    Abstract A cell is the basic unit of life, and death is inevitable for any cell. However, cancer cells that deviate from the normal track can resist death and survive. Ferroptosis is recently discovered as a modulated cell death different from other known forms of cell death in morphology, biochemistry, and genetics. It is characterized by iron-dependent lipid peroxidation regulated by various metabolic pathways. The incidence and mortality of genitourinary system cancer have been increasing recently. Although clinical practice therapy techniques have improved, no plan with a positive prognosis has been identified. For the therapy of More >

  • Open Access

    ARTICLE

    The Neurosurgical Challenge of Primary Central Nervous System Lymphoma Diagnosis: A Multimodal Intraoperative Imaging Approach to Overcome Frameless Neuronavigated Biopsy Sampling Errors

    Oncologie, Vol.24, No.4, pp. 693-706, 2022, DOI:10.32604/oncologie.2022.025393 - 31 December 2022
    Abstract Background: Intracranial lymphoma remains a challenging differential diagnosis in daily neurosurgical practice. We analyzed our early experience with a surgical series of frameless neuronavigated biopsies in Primary CNS Lymphomas (PCNSLs), highlighting the importance of using an intraoperative combined imaging protocol (5-ALA fluorescence, i-CT and 11C-MET-PET) to overcome potential targeting errors secondary to tumor volume reduction after corticosteroid therapy. Materials and Methods: All patients treated for PCNLSs at our center in a 24-month period (1/1/2019 to 31/12/2020) were analyzed. Our cohort included 6 patients (4 males), with a median age of 67 years (59–82). A total of 45 samples… More >

  • Open Access

    ARTICLE

    Nimotuzumab Combined with Neoadjuvant or Induction Chemotherapy for Head and Neck Squamous Cell Carcinoma: A Retrospective Study

    Oncologie, Vol.24, No.4, pp. 707-716, 2022, DOI:10.32604/oncologie.2022.027023 - 31 December 2022
    Abstract Objective: To assess the efficacy and toxicity of nimotuzumab combined with neoadjuvant or induction chemotherapy for head and neck squamous cell carcinoma (HNSCC). Methods: Patients received intravenous nimotuzumab (400 mg, weekly for 1–3 weeks) combined with chemotherapy (5-fluorouracil/paclitaxel/docetaxel + nedaplatin/cisplatin for 1–2 cycles), prior to definitive surgical resection, radiotherapy or other treatments. The primary endpoint was the objective response rate (ORR). The secondary endpoints were tumor downstaging, complete response rate (CRR), partial response rate (PRR), disease control rate (DCR), R0 resection rate, pathological complete response (pCR), larynx preservation rate, overall survival (OS), progression-free survival (PFS), and… More >

  • Open Access

    ARTICLE

    Study on the Value of Ultrasound Elastography Combined with Plasma miRNA Expression in the Early Detection of Breast Cancer

    Oncologie, Vol.24, No.4, pp. 717-727, 2022, DOI:10.32604/oncologie.2022.026998 - 31 December 2022
    (This article belongs to the Special Issue: Biomarkers for Breast Cancer Diagnosis and Treatment Selection: from Basic Research to Practice)
    Abstract Background: Breast cancer (BC) is the most common malignant tumor in women, and its morbidity and mortality are increasing each year, due to the lack of specific clinical symptoms in the early stage of BC, and the lack of diagnostic methods for early breast cancer. Therefore, identifying an effective diagnostic method for early BC has become urgent. Materials and Methods: Breast lesions with a histological diagnosis that were examined by ultrasonic elastography (UE) in our department from June 2020 to December 2021 were reviewed. qRT-PCR was performed to measure the expression levels of miR-144-5p and miR-26b-5p in… More >

  • Open Access

    ARTICLE

    PD-1 Relevant Genes Predict the Prognosis of Breast Cancer and Their Prediction Effect in Tumor Response to Immunotherapy

    Oncologie, Vol.24, No.4, pp. 729-742, 2022, DOI:10.32604/oncologie.2022.026118 - 31 December 2022
    (This article belongs to the Special Issue: Biomarkers for Breast Cancer Diagnosis and Treatment Selection: from Basic Research to Practice)
    Abstract Background: Immunotherapy is becoming a powerful approach in the treatment of breast cancer. However, high response rates in the majority of breast cancer patients have yet to be achieved. Materials and Methods: Based on public data sources, we identified 22 genes that are correlated with PD-1 expression as well as differentially expressed between tumor tissues and normal tissues, and high expression of all the key genes was correlated with a superior survival outcome. Using the least absolute shrinkage and selection operator Cox regression model, a risk score was constructed. Results: A multivariate Cox analysis showed that the… More >

  • Open Access

    ARTICLE

    Research on Clinical Effectiveness of Aspirin for Treating Breast Cancer and Cell Protein Biomarkers on Aspirin Treatment in Drug-Resistant Estrogen Receptor-Positive Breast Cancer Cells

    Oncologie, Vol.24, No.4, pp. 743-768, 2022, DOI:10.32604/oncologie.2022.025419 - 31 December 2022
    (This article belongs to the Special Issue: Biomarkers for Breast Cancer Diagnosis and Treatment Selection: from Basic Research to Practice)
    Abstract Background: Aspirin (ASA) has been reported to have an antitumor effect but the role of ASA in the prevention and treatment of breast cancer (BC) is still controversial. This study aimed to identify clinical effectiveness of ASA in the treatment of BC and explore the antitumor target proteins of ASA that may be involved in overcoming tamoxifen resistance in estrogen receptor (ER)-positive BC cells. Materials and Methods: Randomized controlled trials (RCTs) of ASA in the treatment of BC were queried from the databases, including PubMed, Web of Science, Cochrane Library, WanFang, and Chinese National Knowledge Infrastructure. According… More >

  • Open Access

    ARTICLE

    Angiogenic Gene PTK2 is a Potential Biomarker of Gestational Diabetes Mellitus and is Significantly Associated with Breast Cancer Immune Infiltration

    Oncologie, Vol.24, No.4, pp. 769-787, 2022, DOI:10.32604/oncologie.2022.026248 - 31 December 2022
    Abstract Background: Gestational diabetes mellitus (GDM) affects the health of numerous women around the world. A recent study has shown that GDM is associated with an increased incidence of cancer. In this study, we aimed to explore the possible shared mechanisms and potential common therapeutic targets between GDM and cancer. Methods: The limma package was used to identify differentially expressed genes (DEGs) in GDM. The Cytoscape plugin cytoHubba was used to screen hub genes. The CIBERSORT algorithm was used to explore the correlation between hub genes and immunity. Cox regression analysis was used to assess the relationship… More >

  • Open Access

    ARTICLE

    Identification of Circular RNA hsa-circ-0006969 as a Novel Biomarker for Breast Cancer

    Oncologie, Vol.24, No.4, pp. 789-801, 2022, DOI:10.32604/oncologie.2022.026589 - 31 December 2022
    (This article belongs to the Special Issue: Biomarkers for Breast Cancer Diagnosis and Treatment Selection: from Basic Research to Practice)
    Abstract Background: To investigate the characteristics of circular RNA hsa-circ-0006969 in breast cancer and identify it as a novel biomarker for breast cancer. Methods: Three breast cancer (BC) patient tissues were selected to perform human circRNA microarray analysis. GeneSpring 13.0 (Agilent) software was applied for analyzing the data. Another 116 BC patients were recruited for verification. Hsa-circ-0006969 was found as a potential circRNA for BC diagnostic biomarker. The structure of hsa-circ-0006969 was predicted by circPrimer1.2 software. MiRanda v3.3, RNA hybrid 2.1, and Cytoscape 3.6.0 were used for predicting the networks of circRNA-miRNA. T-test, Curve regression, and ROC… More >

  • Open Access

    ARTICLE

    A Metabolism-Related Gene Signature Predicts the Prognosis of Breast Cancer Patients: Combined Analysis of High-Throughput Sequencing and Gene Chip Data Sets

    Oncologie, Vol.24, No.4, pp. 803-822, 2022, DOI:10.32604/oncologie.2022.026419 - 31 December 2022
    (This article belongs to the Special Issue: Biomarkers for Breast Cancer Diagnosis and Treatment Selection: from Basic Research to Practice)
    Abstract Background and Aim: Hundreds of consistently altered metabolic genes have been identified in breast cancer (BC), but their prognostic value remains to be explored. Therefore, we aimed to build a prediction model based on metabolism-related genes (MRGs) to guide BC prognosis. Methods: Current work focuses on constructing a novel MRGs signature to predict the prognosis of BC patients using MRGs derived from the Virtual Metabolic Human (VMH) database, and expression profiles and clinicopathological data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Results: The 3-MRGs-signature constructed by SERPINA1, QPRT and PXDNL was found… More >

  • Open Access

    ARTICLE

    RCN3 Expression Indicates Prognosis in Colorectal Cancers

    Oncologie, Vol.24, No.4, pp. 823-833, 2022, DOI:10.32604/oncologie.2022.025411 - 31 December 2022
    Abstract Background: Reticulocalbin 3 (RCN3) has been associated with several malignancies. However, its role in colorectal cancer (CRC) remains controversial. Thus, this study aimed to investigate the role of RCN3 in CRC prognosis. Methods: The clinical significance of RCN3 expression in CRC was evaluated in a large cohort of 483 patients. Normal tissues, carcinoma, para-carcinoma, adenoma, and metastatic tissues were evaluated by immunohistochemistry. We investigated the association between RCN3 expression and CRC occurrence in tumors and other tissues. Prognostic factors were also evaluated by Kaplan-Meier survival analysis and the Cox regression model. Results: RCN3 was significantly overexpressed in CRC… More >

  • Open Access

    ARTICLE

    Comprehensive Analysis of the Expression and Clinical Significance of a Ferroptosis-Related Genome in Ovarian Serous Cystadenocarcinoma: A Study Based on TCGA Data

    Oncologie, Vol.24, No.4, pp. 835-863, 2022, DOI:10.32604/oncologie.2022.026447 - 31 December 2022
    (This article belongs to the Special Issue: Ferroptosis in the Occurrence and Treatment of Cancer)
    Abstract Background: Epithelial ovarian cancer (EOC) is the deadliest malignancy among the gynecologic tumors, and ovarian serous cystadenocarcinoma (OV) is the dominant histological type. Ferroptosis is a novel iron-dependent, programmed form of cell death, and agents that trigger ferroptosis may constitute potential anti-cancer therapies. Materials and Methods: We herein extracted the genes that participate in the process of ferroptosis from the online FerrDb database to create a ferroptosis-related genome (FRG), and then comprehensively analyzed the relationship between the mRNA expression of each gene and the clinicopathologic features of The Cancer Genome Atlas (TCGA)-OV cohort. Results: We found that… More >

  • Open Access

    ARTICLE

    Racial Disparities in Clinical Features and Survival Outcomes among Patients with Pancreatic Neuroendocrine Tumor: A Contemporary SEER Database Analysis

    Oncologie, Vol.24, No.4, pp. 865-895, 2022, DOI:10.32604/oncologie.2022.025447 - 31 December 2022
    Abstract Objective: The characteristics of clinical features and prognoses among patients with different racial backgrounds have not been clearly studied. We thus investigated the clinical characteristics and overall survival (OS) differences among Asian, White, and Black patients with pancreatic neuroendocrine tumors (pNETs). Materials and Methods: The Surveillance, Epidemiology, and End Results (SEER) database was queried to identify patients with pNETs between 1983 and 2015. We performed univariable (UVA) and multivariable logistic regression (MVA) to assess the association between variables and race category. A Kaplan-Meier (KM) plot was used to calculate the OS rates. The Cox proportional hazard regression… More >

  • Open Access

    ARTICLE

    MiR-145-5p Suppresses Hepatocellular Carcinoma Progression by Targeting ABHD17C

    Oncologie, Vol.24, No.4, pp. 897-912, 2022, DOI:10.32604/oncologie.2022.025693 - 31 December 2022
    Abstract Background: MicroRNA-145-5p (miR-145-5p) reportedly inhibits hepatocellular carcinoma (HCC) by targeting ARF6, SPATS2, CDCA3, KLF5, and NRAS, indicating that miR-145-5p plays an important role in the occurrence and development of HCC by regulating the expression of various genes. In this study, we aimed to explore novel downstream targets of miR-145-5p and elucidate the potential mechanism of miR-145-5p in HCC. Materials and Methods: A bioinformatics analysis was performed to determine the clinical significance of miR-145-5p and alpha/beta hydrolase domain-containing protein 17C (ABHD17C) in patients with HCC. The ability of Hep3B cells to proliferate, migrate, and invade was examined after… More >

  • Open Access

    ARTICLE

    Expression and Clinical Significance of ACTA2 in Osteosarcoma Tissue

    Oncologie, Vol.24, No.4, pp. 913-925, 2022, DOI:10.32604/oncologie.2022.026296 - 31 December 2022
    Abstract Objective: To investigate the expression of alpha–smooth muscle actin (ACTA2) in osteosarcoma tissues and its relationship with prognosis. Methods: Prognostic analysis of lung metastasis–related genes in osteosarcoma using the TCGA database. Single-cell sequencing detected the expression of ACTA2 in 11 osteosarcoma tissues. Paraf- fin-embedded tissues of 74 osteosarcoma patients treated at the Sixth People’s Hospital of Shanghai Jiao Tong University from 2014 to 2019 were collected, and tissue microarrays were prepared. ACTA2 expression was detected and scored by immunohistochemistry. According to the median value of the ACTA2 histochemical score, 74 patients were divided into two groups, the… More >

  • Open Access

    CASE REPORT

    Multiple Recurrence of Primary Orbital Synovial Sarcoma: Report of Two Cases and Literature Review

    Oncologie, Vol.24, No.4, pp. 927-935, 2022, DOI:10.32604/oncologie.2022.026720 - 31 December 2022
    Abstract Synovial sarcoma (SS) is typically an aggressive malignant soft tissue tumor that mostly affects adolescents and young adults. It is extremely rare in orbit and carries a high risk of recurrence and metastasis, posing a challenge to ophthalmologists in diagnosing and managing. We present two primary orbital synovial sarcoma cases with unilateral exophthalmos and limited motility. Both male patients underwent reoperation in our hospital since tumor recurrence; the pathologic diagnoses were biphasic type and occult type, respectively. Both cases were positive for EMA and CK, and SOX-9 and INI-1 were newly discovered immune markers. Fluorescence in More >

  • Open Access

    CASE REPORT

    Differential Diagnosis between Primary Intracranial Melanoma and Cerebral Cavernoma in Crohn’s Disease: A Case Report and Literature Review

    Oncologie, Vol.24, No.4, pp. 937-942, 2022, DOI:10.32604/oncologie.2022.027155 - 31 December 2022
    Abstract Primary intracranial melanomas are rare, with a challenging diagnosis based only on clinical and imaging features. The authors described the case of an intracerebral right parieto-temporal melanoma mimicking a cavernoma in a patient affected by Crohn’s disease. A 67-year-old female patient with Crohn’s disease and small bowel stenosis was hospitalized for surgical removal of the terminal ileum and latero-lateral ileo-colic anastomosis. During postoperative week 1, the patient developed psychomotor agitation followed by altered consciousness. An urgent brain CT showed a right intracerebral parieto-temporal hemorrhage with intralesional calcifications. The patient underwent a decompressive craniectomy with hematoma More >

Copyright © 2024 The Author(s). Published by Tech Science Press.

Share Link